For research teamsHelp me find a study
Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1743studies shown
Showing 265-276 of 1,743
Drug study icon
CompletedEUCTR 2014-004588-19

A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Tre...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
DepressionDrugA study involving a medication or substance.
Countries
United Kingdom, Belgium, Bulgaria, ...
Sponsor
Janssen-Cilag International NV
Condition
Depression
View study
Drug study icon
TerminatedEUCTR 2017-001084-20

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects W...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom
Sponsor
Takeda Development Centre Europe Ltd.
Condition
Schizophrenia
View study
Drug study icon
TerminatedEUCTR 2017-002232-16

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
DepressionDrug
Countries
United Kingdom
Sponsor
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
Condition
Depression
View study
Drug study icon
CompletedEUCTR 2012-000418-13

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom
Sponsor
AbbVie Deutschland GmbH & Co. KG
Condition
Schizophrenia
View study
Drug study icon
TerminatedEUCTR 2012-005000-17

A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
OCDDrug
Countries
United Kingdom, Bulgaria, Czechia, ...
Sponsor
Novartis Pharma Services AG
Condition
OCD
View study
Drug study icon
CompletedEUCTR 2005-003006-29

A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
AnxietyDrug
Countries
United Kingdom, Germany
Sponsor
Pfizer Limited
Condition
Anxiety
View study
Drug study icon
CompletedEUCTR 2012-003209-92

A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cogniti...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom, Italy, Poland
Sponsor
Forum Pharmaceuticals, Inc.
Condition
Schizophrenia
View study
Drug study icon
TerminatedEUCTR 2012-001357-10

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg a...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Depression, BipolarityDrug
Countries
United Kingdom, Bulgaria, Czechia, ...
Sponsor
Takeda Global Research & Development Centre (Europe) Ltd (TGRD)
Condition
Depression, Bipolarity
View study
Drug study icon
CompletedEUCTR 2010-020008-31

A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom
Sponsor
ACADIA Pharmaceuticals Inc
Condition
Schizophrenia
View study
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.